Erythropoietin stimulating agents in the management of anemia of chronic kidney disease.

Patient Preference and Adherence
Amir HayatMoro O Salifu

Abstract

Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is deficient in the majority of patients with advanced kidney disease thereby predisposing to anemia. Since the approval of recombinant human erythropoietin (epoetin alfa) by the US FDA in 1989, epoetin alfa and similar agents now collectively known as erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of the erythropoietin-deficient anemia that occurs in most patients with CKD. In this review, we have outlined the considerations that need to be taken into account when prescribing ESA for the treatment of anemia in CKD.

References

Jul 20, 1989·The New England Journal of Medicine·J W EschbachJ W Adamson
Nov 1, 1993·Kidney International·P H MaxwellP J Ratcliffe
Feb 24, 2001·ASAIO Journal : a Peer-reviewed Journal of the American Society for Artificial Internal Organs·M TonelliN Muirhead
Sep 5, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Y Le MeurV Praloran
May 29, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Olimpia OrtegaAna Vigil
Jul 16, 2003·Annals of Internal Medicine·Andrew S LeveyUNKNOWN National Kidney Foundation
Sep 23, 2003·Clinical Chemistry·Carlo Brugnara
Dec 24, 2003·Kidney & Blood Pressure Research·George TsirpanlisChrysoula Nicolaou
Sep 24, 2004·Current Medical Research and Opinion·William McClellanMarc Leiserowitz
May 9, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·UNKNOWN KDOQI, UNKNOWN National Kidney Foundation
Aug 11, 2006·Current Diabetes Reports·Samy I McFarlaneJames R Sowers
Nov 17, 2006·The New England Journal of Medicine·Tilman B DrüekeUNKNOWN CREATE Investigators
Nov 17, 2006·The New England Journal of Medicine·Ajay K SinghUNKNOWN CHOIR Investigators
Apr 19, 2007·JAMA : the Journal of the American Medical Association·Mae ThamerMiguel A Hernán
May 29, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Peter Bárány, Hans-Joachim Müller
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Robert N Foley
Sep 19, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Jay B Wish
Aug 28, 2007·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·UNKNOWN KDOQI
Dec 14, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Iain C Macdougall
Jan 8, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Carol PollockEdwin Toffelmire

❮ Previous
Next ❯

Citations

Apr 5, 2016·Indian Journal of Endocrinology and Metabolism·Sarita BajajSushil Kumar
Feb 1, 2018·International Journal of Molecular Sciences·Joshua M KaplanSean Dikdan

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
blood draws
biopsy

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Jérôme RossertWilliam McClellan
The New England Journal of Medicine
Ajay K SinghCHOIR Investigators
© 2022 Meta ULC. All rights reserved